Patient-derived Xenograft Models in Cancer Therapy: Technologies and Applications

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2023 Apr 12

PMID 37045827

Authors

Yihan Liu

Wantao Wu

Changjing Cai

Hao Zhang

Hong Shen

Ying Han

Affiliations

Soon will be listed here.

Abstract

Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted into immunocompromised or humanized mice, have shown superiority in recapitulating the characteristics of cancer, such as the spatial structure of cancer and the intratumor heterogeneity of cancer. Moreover, PDX models retain the genomic features of patients across different stages, subtypes, and diversified treatment backgrounds. Optimized PDX engraftment procedures and modern technologies such as multi-omics and deep learning have enabled a more comprehensive depiction of the PDX molecular landscape and boosted the utilization of PDX models. These irreplaceable advantages make PDX models an ideal choice in cancer treatment studies, such as preclinical trials of novel drugs, validating novel drug combinations, screening drug-sensitive patients, and exploring drug resistance mechanisms. In this review, we gave an overview of the history of PDX models and the process of PDX model establishment. Subsequently, the review presents the strengths and weaknesses of PDX models and highlights the integration of novel technologies in PDX model research. Finally, we delineated the broad application of PDX models in chemotherapy, targeted therapy, immunotherapy, and other novel therapies.

Citing Articles

Establishment and Its Utility of a Patient-Derived Cell Xenografts (PDCX) Model with Cryopreserved Cancer Cells from Human Tumor.

Kim K, Lee J, Lee E, Jung D, Goh A, Choi M Cells. 2025; 14(5).

PMID: 40072054 PMC: 11898490. DOI: 10.3390/cells14050325.

Establishment of a novel mouse model of colorectal cancer by orthotopic transplantation.

Chen C, Fu Q, Wang L, Tanaka S, Imajo M BMC Cancer. 2025; 25(1):405.

PMID: 40050746 PMC: 11884030. DOI: 10.1186/s12885-025-13834-5.

Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: and anticancer activities and newly discovered effects on cancer metabolic pathways.

Wang W, Aguilar M, Datta S, Alley A, Tadesse M, Wang X Front Pharmacol. 2025; 16:1531667.

PMID: 40046748 PMC: 11879958. DOI: 10.3389/fphar.2025.1531667.

Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application.

Marton E, Varga A, Domoszlai D, Buglyo G, Balazs A, Penyige A Cancers (Basel). 2025; 17(4).

PMID: 40002172 PMC: 11853212. DOI: 10.3390/cancers17040579.

Nanoparticle-Mediated mRNA Delivery to Triple-Negative Breast Cancer (TNBC) Patient-Derived Xenograft (PDX) Tumors.

El-Sahli S, Manturthi S, Durocher E, Bo Y, Akman A, Sannan C ACS Pharmacol Transl Sci. 2025; 8(2):460-469.

PMID: 39974646 PMC: 11833720. DOI: 10.1021/acsptsci.4c00597.

References

Mourragui S, Loog M, Vis D, Moore K, Manjon A, van de Wiel M . Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning. Proc Natl Acad Sci U S A. 2021; 118(49). PMC: 8670522. DOI: 10.1073/pnas.2106682118. View

Grosselin K, Durand A, Marsolier J, Poitou A, Marangoni E, Nemati F . High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. Nat Genet. 2019; 51(6):1060-1066. DOI: 10.1038/s41588-019-0424-9. View

Hu B, Li H, Guo W, Sun Y, Zhang X, Tang W . Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. Int J Cancer. 2019; 146(6):1606-1617. DOI: 10.1002/ijc.32564. View

Liu Y, Yang M, Deng Y, Su G, Enninful A, Guo C . High-Spatial-Resolution Multi-Omics Sequencing via Deterministic Barcoding in Tissue. Cell. 2020; 183(6):1665-1681.e18. PMC: 7736559. DOI: 10.1016/j.cell.2020.10.026. View

Ni W, Mo H, Liu Y, Xu Y, Qin C, Zhou Y . Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation. Mol Ther. 2021; 29(10):2995-3010. PMC: 8530930. DOI: 10.1016/j.ymthe.2021.05.012. View

Carvalho M, Barata D, Teixeira L, Giselbrecht S, Reis R, Oliveira J . Colorectal tumor-on-a-chip system: A 3D tool for precision onco-nanomedicine. Sci Adv. 2019; 5(5):eaaw1317. PMC: 6531003. DOI: 10.1126/sciadv.aaw1317. View

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

Kawashima N, Ishikawa Y, Kim J, Ushijima Y, Akashi A, Yamaguchi Y . Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells. Nat Commun. 2022; 13(1):1624. PMC: 8956585. DOI: 10.1038/s41467-022-29304-6. View

Ma J, Fong S, Luo Y, Bakkenist C, Shen J, Mourragui S . Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients. Nat Cancer. 2021; 2(2):233-244. PMC: 8248912. DOI: 10.1038/s43018-020-00169-2. View

10.

Bonazzi V, Kondrashova O, Smith D, Nones K, Sengal A, Ju R . Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. Genome Med. 2022; 14(1):3. PMC: 8751371. DOI: 10.1186/s13073-021-00990-z. View

11.

Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J . Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. 2021; 40(37):5590-5599. PMC: 8445818. DOI: 10.1038/s41388-021-01911-5. View

12.

Contreras-Trujillo H, Eerdeng J, Akre S, Jiang D, Contreras J, Gala B . Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. Nat Commun. 2021; 12(1):6522. PMC: 8586369. DOI: 10.1038/s41467-021-26771-1. View

13.

Zhan M, Yang R, Wang H, He M, Chen W, Xu S . Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients. Cancer Commun (Lond). 2018; 38(1):48. PMC: 6050666. DOI: 10.1186/s40880-018-0318-8. View

14.

Jo H, Yagishita S, Hayashi Y, Ryu S, Suzuki M, Kohsaka S . Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non-small Cell Lung Cancer PDX Models with Driver Genetic Alterations. Mol Cancer Ther. 2021; 21(2):359-370. DOI: 10.1158/1535-7163.MCT-21-0371. View

15.

Dang H, Krasnick B, White B, Grossman J, Strand M, Zhang J . The clonal evolution of metastatic colorectal cancer. Sci Adv. 2020; 6(24):eaay9691. PMC: 7286679. DOI: 10.1126/sciadv.aay9691. View

16.

Cayrefourcq L, Thomas F, Mazard T, Assenat E, Assou S, Alix-Panabieres C . Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones. Mol Cancer. 2021; 20(1):30. PMC: 7869222. DOI: 10.1186/s12943-021-01326-6. View

17.

Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S . B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res. 2017; 23(15):4212-4223. PMC: 5540787. DOI: 10.1158/1078-0432.CCR-16-2703. View

18.

Lazzari L, Corti G, Picco G, Isella C, Montone M, Arcella P . Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clin Cancer Res. 2019; 25(20):6243-6259. PMC: 7611232. DOI: 10.1158/1078-0432.CCR-18-3440. View

19.

Roy S, Whitehead T, Li S, Ademuyiwa F, Wahl R, Dehdashti F . Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2021; 49(2):550-562. PMC: 8800941. DOI: 10.1007/s00259-021-05489-8. View

20.

Ramzy G, Koessler T, Ducrey E, McKee T, Ris F, Buchs N . Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. Cancers (Basel). 2020; 12(6). PMC: 7352800. DOI: 10.3390/cancers12061423. View